Calidi Biotherapeutics
CLDI
34 hedge funds and large institutions have $656K invested in Calidi Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 6 closing their positions.
0.06% less ownership
Funds ownership: 0.11% → 0.05% (-0.06%)
3% less funds holding
Funds holding: 35 → 34 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
79% less capital invested
Capital invested by funds: $3.09M → $656K (-$2.44M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$28.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$18.2K |
| 3 |
HF
HRT Financial
New York
|
+$17.6K |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$12.6K |
| 5 |
Goldman Sachs
New York
|
+$5.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.02M |
| 2 |
RCI
RS Crum Inc
Newport Beach,
California
|
-$31.3K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$27.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18.5K |
| 5 |
VF
Virtu Financial
New York
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EWM
26
Evermay Wealth Management
Arlington,
Virginia
| $1.46K | – | – | – |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
BC
28
Barrett & Company
Providence,
Rhode Island
| $805 | – | – | – |
|
29
Morgan Stanley
New York
| $441 | -$78 | -1 | -9% |
|
|
TCM
30
Tradewinds Capital Management
Bellingham,
Washington
| $230 | – | – | – |
|
|
SS
31
SBI Securities
Tokyo,
Japan
| $129 | +$78 | +1 | +50% |
|
|
CFO
32
CVA Family Office
Denver,
Colorado
| $115 | – | – | – |
|
33
Bank of America
Charlotte,
North Carolina
| $75 | +$78 | +1 | +100% |
|
34
BlackRock
New York
| $60 | – | – | – |
|
35
JP Morgan Chase
New York
| $14 | – | – | – |
|
|
RCI
36
RS Crum Inc
Newport Beach,
California
| – | -$31.3K | -288 | Closed |
|
|
37
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$18.5K | -170 | Closed |
|
|
TSS
38
Two Sigma Securities
New York
| – | -$11.5K | -106 | Closed |
|
|
XT
39
XTX Topco
George Town,
Cayman Islands
| – | -$9.08K | -84 | Closed |
|
|
AMH
40
Apollo Management Holdings
New York
| – | -$7.08K | -65 | Closed |
|
|
NA
41
NewEdge Advisors
New Orleans,
Louisiana
| – | -$6.23K | -57 | Closed |
|
CLDI Hedge Fund Activity: Q2 2025 in Review
34 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q2 2025, worth a combined $656K — down 79% from $3.09M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CLDI and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $28.8K. The largest seller was Armistice Capital, cutting an estimated $1.02M.
- 34 institutional investors held Calidi Biotherapeutics (CLDI) as of Q2 2025, down from 35 in Q1 2025.
- Funds reported $656K of Calidi Biotherapeutics stock for Q2 2025, down 79% quarter-over-quarter.
- 5 funds opened new Calidi Biotherapeutics positions in Q2 2025 and 6 closed out, a net change of -1 holder.
- The largest Calidi Biotherapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $28.8K added.
- The largest Calidi Biotherapeutics seller in Q2 2025 was Armistice Capital, an estimated $1.02M sold.
Based on aggregated 13F filings for Q2 2025.